邁克生物(300463.SZ):半年度淨利潤預降50%-65%
格隆匯7月16日丨邁克生物(300463.SZ)公佈,預計2023年半年度實現營業收入12.47億元-14.25億元,同比下降20%-30%;歸屬於上市公司股東的淨利潤1.42億元-2.03億元,同比下降50%-65%;扣除非經常性損益後的淨利潤1.40億元-2億元,同比下降50%-65%。
報吿期內,一方面受市場需求變化帶來的影響,公司自主產品中分子診斷產品銷售收入出現大幅下滑,同時相關存貨減值準備計提有所增加,導致營業收入及淨利潤同比下降。另一方面公司自主產品已逐漸具備在生化、免疫、尿液、血細胞、凝血等多平台產品系列化系統化以及整體實驗室自動化解決方案,公司加速自主產品營銷體系建設,不斷優化產品結構,報吿期內代理產品銷售收入同比下降。
報吿期內,預計非經常性損益對淨利潤的影響為-350萬元左右,主要系政府補助和設備更新報廢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.